# Agenovir

**Canonical:** https://apis.io/providers/agenovir/  
**APIs profiled:** 0

Agenovir Corporation was a biotechnology company founded in 2014 to develop a novel class of human therapeutics targeting diseases caused by latent or persistent viral reservoirs. Built on CRISPR/Cas9 and other nuclease technology from the Stephen Quake lab at Stanford, it designed and simulated nucleases in silico at scale to disrupt intracellular viral DNA. It raised a $10.6M Series A led by DCVC (Data Collective) with Celgene and Lightspeed Venture Partners, and was acquired by Vir Biotechnology in 2018. It is a therapeutics company with no public developer, API, or SDK surface.

## Kin Score — 2.2 / 100 (minimal)

Scored 2026-08-20 under rubric 0.12.0. Trend: flat (+0.0 from 2.2).

| Facet | Score |
|---|---|
| Discoverability | 50.0 |
| Contract Quality | 0.0 |
| Governance | 0.0 |
| Contract Governance | 0.0 |
| Operational Transparency | 0.0 |
| Developer Ergonomics | 0.0 |
| Commercial Clarity | 0.0 |
| Access Clarity | 0.0 |

Regulatory layer — **Health**: 0.0 (matched via tags).

## Agent readiness — 0.0 (human-only)

| Dimension | Value |
|---|---|
| Spec Presence | no |
| Agentic Access | no |
| Reversibility Documented | no |
| MCP Server | no |
| Auth Clarity | no |
| Idempotency | no |
| Error Semantics | no |
| OpenAPI Examples | no |
| Rate Limit Signal | no |
| Event Surface Described | no |
| Agent Skills | no |
| Well Known Catalog | no |
| Consent Identity | no |
| Agent Card | no |
| Dry Run Mode | no |

## Access

Unknown — onboarding: unknown, pricing: unknown, trial: no (confidence: low).

## Tags

Company, Biotechnology, Therapeutics, CRISPR, Gene Editing, Antiviral, Life Sciences, Acquired

---

Profiled by [API Evangelist](https://apievangelist.com) and published on [APIs.io](https://apis.io/providers/agenovir/). Scores are computed from the provider's own public artifacts under a published rubric.